{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:14:35Z","timestamp":1780056875844,"version":"3.54.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.diabres.2005.03.012","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T13:54:25Z","timestamp":1113486865000},"page":"S22-S29","source":"Crossref","is-referenced-by-count":27,"special_numbering":"S1","title":["Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies"],"prefix":"10.1016","volume":"68","author":[{"given":"Francesco","family":"Giorgino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Laviola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Leonardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2005.03.012_bib1","unstructured":"ADA, Clinical Practice Recommendations, Diabetes Care, 2004."},{"key":"10.1016\/j.diabres.2005.03.012_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0149-2918(04)90132-4","article-title":"New strategies for basal insulin treatment in type 2 diabetes mellitus","volume":"26","author":"Dailey","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diabres.2005.03.012_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 6A","key":"10.1016\/j.diabres.2005.03.012_bib4","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(02)01276-7","article-title":"Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities","volume":"113","author":"LeRoith","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diabres.2005.03.012_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1172\/JCI6609","article-title":"Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance","volume":"103","author":"Virkamaki","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabres.2005.03.012_bib6","series-title":"Frontiers in Animal Diabetes Research: Muscle Metabolism","doi-asserted-by":"crossref","DOI":"10.1201\/9780203166420.ch3","article-title":"Defects in intermediate insulin signaling in skeletal muscle: phophatidylinositol (PI) 3-kinase and glucose transport","author":"Giorgino","year":"2002"},{"key":"10.1016\/j.diabres.2005.03.012_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11892-003-0018-9","article-title":"Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium","volume":"3","author":"Vincent","year":"2003","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.diabres.2005.03.012_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11892-003-0064-3","article-title":"Surgical removal of visceral adipose tissue: effects on insulin action","volume":"3","author":"Gabriely","year":"2003","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.diabres.2005.03.012_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/diabetes.48.4.839","article-title":"Effects of weight loss on regional fat distribution and insulin sensitivity in obesity","volume":"48","author":"Goodpaster","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.012_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.ijo.0802326","article-title":"Integrative physiology of human adipose tissue","volume":"27","author":"Frayn","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.diabres.2005.03.012_bib11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s001250051075","article-title":"Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway","volume":"41","author":"Zierath","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2005.03.012_bib12","first-page":"309","article-title":"Insulin signaling in human adipose tissue depots in vivo","volume":"52","author":"Perrini","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.012_bib13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.diabres.2005.03.012_bib14","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.03.012_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/bbrc.1999.1488","article-title":"Inhibition of adipogenesis by COOH-terminally truncated mutant of PPARgamma2 in 3T3-L1 cells","volume":"264","author":"Masugi","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.diabres.2005.03.012_bib16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/diabetes.52.5.1265","article-title":"The peroxisome proliferator-activated receptor-gamma2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood: the Bogalusa Heart Study","volume":"52","author":"Li","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.012_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2337\/diacare.26.3.825","article-title":"Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes","volume":"26","author":"Bluher","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.03.012_bib18","first-page":"444","article-title":"Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide","volume":"293","author":"Hu","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.diabres.2005.03.012_bib19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/diacare.24.6.983","article-title":"Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes","volume":"24","author":"Hollander","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.03.012_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.012_bib21","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2004-0699","article-title":"Sulphonylurea induced beta-cell apoptosis in cultured human islets","author":"Maedler","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.diabres.2005.03.012_bib22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2005.03.012_bib23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2337\/diacare.26.8.2231","article-title":"Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients","volume":"26","author":"Alvarsson","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.03.012_bib24","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/j.amjmed.2003.10.017","article-title":"Type 2 diabetes mellitus: what is the optimal treatment regimen?","volume":"116","author":"Bell","year":"2004","journal-title":"Am. J. Med."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T09:59:02Z","timestamp":1548583142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822705000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":24,"alternative-id":["S0168822705000537"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2005.03.012","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}